Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Post-MGUS diagnosis serum monoclonal-protein velocity and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Chang SH, Gumbel J, Luo S, Thomas TS, Sanfilippo KM, Luo J, Colditz GA, Carson KR.

Cancer Epidemiol Biomarkers Prev. 2019 Sep 9. pii: cebp.0132.2019. doi: 10.1158/1055-9965.EPI-19-0132. [Epub ahead of print]

PMID:
31501149
2.

Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.

Chang SH, Luo S, O'Brian KK, Thomas TS, Colditz GA, Carlsson NP, Carson KR.

Lancet Haematol. 2015 Jan;2(1):e30-6. Erratum in: Lancet Haematol. 2015 Feb;2(2):e54.

3.

Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP, Carson KR.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw264. Print 2017 May.

4.

Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).

Viera S, Ludek P, Zdeněk A, Marta K, Martin Š, Sabina Š, Zdeněk K.

Klin Onkol. Summer 2018;31(4):270-276. doi: 10.14735/amko2018270. Review.

PMID:
30541309
5.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY.

JAMA Oncol. 2015 May;1(2):168-74. doi: 10.1001/jamaoncol.2015.23.

PMID:
26181017
6.

Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.

Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT.

Lancet Haematol. 2017 Dec;4(12):e584-e594. doi: 10.1016/S2352-3026(17)30209-0. Epub 2017 Nov 13.

7.

[Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].

Adam Z, Krejčí M, Pour L, Sevčíková E, Křivanová A, Rehák Z, Koukalová R, Cermáková Z, Vaníček J, Sevčíková S.

Vnitr Lek. 2014 Oct;60(10):861-79. Review. Czech.

PMID:
25382009
8.

Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.

Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N.

Am J Nephrol. 2012;35(4):365-71. doi: 10.1159/000337482. Epub 2012 Apr 2.

PMID:
22473253
9.

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1568. [Epub ahead of print]

PMID:
31318385
10.

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY.

Blood Adv. 2017 Nov 1;1(24):2186-2192. doi: 10.1182/bloodadvances.2017007609. eCollection 2017 Nov 14.

11.

Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

Spira D, Weisel K, Brodoefel H, Schulze M, Kaufmann S, Horger M.

Acad Radiol. 2012 Jan;19(1):89-94. doi: 10.1016/j.acra.2011.09.016.

PMID:
22142681
12.

Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.

Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L.

Biol Blood Marrow Transplant. 2014 Mar;20(3):319-25. doi: 10.1016/j.bbmt.2013.11.022. Epub 2013 Dec 1.

13.

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV.

N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.

14.

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.

Steiner N, Göbel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E.

Oncotarget. 2017 Dec 18;9(2):2344-2356. doi: 10.18632/oncotarget.23412. eCollection 2018 Jan 5.

15.

[Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma].

Yang S, Wang W, Jin H, Zhong Y, Xie X.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(4):371-378. Chinese.

PMID:
27868410
16.

Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort.

Lee YG, Bang SM, Lee JO, Kim JW, Lee KW, Kim JH, Song JH, Kim TH, Kim KW, Lee JS.

Cancer Res Treat. 2015 Apr;47(2):215-20. doi: 10.4143/crt.2013.262. Epub 2014 Aug 29.

17.

[Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].

Ščudla V, Petrová P, Pika T, Lochman P, Minařík J, Bačovský J, Srovnalík K.

Cas Lek Cesk. 2015;154(4):181-8. Czech.

PMID:
26357861
18.
19.

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ 3rd, Rajkumar SV.

Blood. 2010 Sep 23;116(12):2019-25; quiz 2197. doi: 10.1182/blood-2010-04-277566. Epub 2010 May 21.

20.

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.

Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Review.

PMID:
27161311

Supplemental Content

Support Center